Company news

Abera Bioscience AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ABERA: 7% organic growth and stable margins in Q1 2026, with strong energy and infrastructure demand

May 12, 2026

ABERA: Transition to clinical-stage vaccines, strong financing, and expanded R&D drive future growth

February 12, 2026

ABERA: Secured funding and positive R&D milestones drive clinical progress despite ongoing losses

November 13, 2025

ABERA: Positive preclinical results and new funding drive clinical trial preparations and liquidity

August 21, 2025

ABERA: Positive Q1 2025 result and strong vaccine pipeline progress, supported by grants

May 13, 2025

ABERA: Strong grants and preclinical results position Abera for growth in mucosal vaccines

February 13, 2025

ABERA: Q3 2024 saw grant-driven revenue, reduced losses, and pipeline expansion for Abera Bioscience

November 13, 2024

ABERA: Net loss narrowed and vaccine pipeline advanced as new lab and funding boosted operations

August 21, 2024

Decks